For research use only. Not for therapeutic Use.
Pyrotinib (CAT: I008931), also known as SHR-1258, is a dual kinase inhibitor targeting both the epidermal growth factor receptor (EGFR or HER-1) and the human epidermal growth factor receptor 2 (ErbB2 or HER-2). It is administered orally and exhibits potential antineoplastic activity. Pyrotinib works by binding to and inhibiting the activity of EGFR and HER2, leading to the inhibition of tumor growth, angiogenesis, and regression in tumor cells expressing these receptors. EGFR and HER2 are receptor tyrosine kinases that are overexpressed in various tumor types, playing critical roles in tumor cell proliferation and the development of tumor blood vessels. Pyrotinib’s dual inhibition of EGFR and HER2 makes it a promising candidate for targeted cancer therapy.
| Catalog Number | I008931 |
| CAS Number | 1269662-73-8 |
| Synonyms | Pyrotinib; SHR-1258; SHR1258; SHR 1258; Pyrotinib maleate;(R,E)-N-(4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-3-(1-methylpyrrolidin-2-yl)acrylamide |
| Molecular Formula | C32H31ClN6O3 |
| Purity | ≥95% |
| Target | EGFR inhibitor |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| Related CAS | 1397922-61-0 |
| Overview of Clinical Research | <span style=”color:#000000;”><span style=”font-family:arial,helvetica,sans-serif;”><span style=”font-size:12px;”>Pyrotinib is an ERBB 2 receptor antagonist. The <span style=”font-variant-ligatures: normal; orphans: 2; widows: 2;”>Phase-III clinical trials in Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in Belgium (PO) (EudraCT2020-000951-11) are ongoing.</span></span></span></span> |
| IUPAC Name | (E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide |
| InChI | InChI=1S/C32H31ClN6O3/c1-3-41-30-17-27-25(16-28(30)38-31(40)12-10-24-8-6-14-39(24)2)32(21(18-34)19-36-27)37-22-9-11-29(26(33)15-22)42-20-23-7-4-5-13-35-23/h4-5,7,9-13,15-17,19,24H,3,6,8,14,20H2,1-2H3,(H,36,37)(H,38,40)/b12-10+/t24-/m1/s1 |
| InChIKey | SADXACCFNXBCFY-IYNHSRRRSA-N |
| SMILES | O=C(NC1=C(OCC)C=C2N=CC(C#N)=C(NC3=CC=C(OCC4=NC=CC=C4)C(Cl)=C3)C2=C1)/C=C/[C@@H]5N(C)CCC5 |
| Reference | <br /> |
